ReviewDrug delivery2023
Polydopamine nanomaterials and their potential applications in the treatment of autoimmune diseases.
Review in Drug delivery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- UCHL3 drives ferroptosis in nucleus pulposus cells by deubiquitinating HMGB1 to activate NCOA4-mediated ferritinophagy.Autophagy · 2026Article
- A Peritoneum-Inspired Biomimetic Asymmetric Patch for Functional Repair and Anti-Adhesion in Abdominal Wall Defects.Advanced healthcare materials · 2026Article
- Advances in Polydopamine-Based Nanoplatforms: Antioxidant Mechanisms and Applications in Oxidative Stress-Mediated Diseases.Nano-micro letters · 2026Review
- Nanoengineered bile acid-mediated orchestration of versatile immuno-microbial cues for treating periodontitis.Journal of nanobiotechnology · 2026Article
- Camouflaged nanorobots target and regulate macrophage subcellular organelle crosstalk patterns to promote neural regeneration.Nature communications · 2026Article
- Hollow-core polydopamine nanocarriers for ultrasound-enhanced drug delivery.Nanoscale horizons · 2026Article
- Advances in biomimetic mineralized biomaterials for bone tissue engineering.Regenerative biomaterials · 2026Review
- Photothermal Therapy Combined with Chemotherapy and Anti-Inflammation Therapy Weakens the Immunosuppression of Cervical Cancer.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Blood compatibility evaluation of polydopamine nanoparticles.Frontiers in pharmacology · 2025Article
- Effect of Polydopamine Nanoparticle-Induced Surface Modification on Demineralized Dentin for Enhanced Functional Remineralization.Journal of pharmacy & bioallied sciences · 2024Article
- Polydopamine-Coated Kaempferol-Loaded MOF Nanoparticles: A Novel Therapeutic Strategy for Postoperative Neurocognitive Disorder.International journal of nanomedicine · 2024Article
- A Multifunctional Nanodrug Co-Delivering VEGF-siRNA and Dexamethasone for Synergistic Therapy in Ocular Neovascular Diseases.International journal of nanomedicine · 2024Article
- Multifunctionally disordered TiOTheranostics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The conventional treatment methods used for the management of autoimmune diseases (ADs) have limited efficacy and also exhibit significant side effects. Thus, identification of novel strategies to improve the efficacy and safety of ADs treatment is urgently required. Overactivated immune response and oxidative stress are common characteristics associated with ADs. Polydopamine (PDA), as a polymer material with good antioxidant and photothermal conversion properties, has displayed useful application potential against ADs. In addition, PDA possesses good biosafety, simple preparation, and easy functionalization, which is conducive for the pharmacological development of PDA nanomaterials with clinical transformation prospects. Here, we have first reviewed the preparation of PDA, the different functional integration strategies of PDA-based biomaterials, and their potential applications in ADs. Next, the mechanism of action of PDA in ADs has been elaborated in detail. Finally, the application opportunities and challenges linked with PDA nanomaterials for ADs treatment are discussed. This review is contributed to design reasonable and effective PDA nanomaterials for the diagnosis and treatment of ADs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.